Summary Workshop Report: Facilitating Oral Product Development and Reducing Regulatory Burden Through Novel Approaches to Assess Bioavailability/Bioequivalence
Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 3
Abstract
This summary workshop report highlights presentations and over-arching themes from an October 2011 workshop. Discussions focused on best practices in the application of biopharmaceutics in oral drug product development and evolving bioequivalence approaches. Best practices leverage biopharmaceutic data and other drug, formulation, and patient/disease data to identify drug development challenges in yielding a successfully performing product. Quality by design and product developability paradigms were discussed. Development tools include early development strategies to identify critical absorption factors and oral absorption modeling. An ongoing theme was the desire to comprehensively and systematically assess risk of product failure via the quality target product profile and root cause and risk analysis. However, a parallel need is reduced timelines and fewer resources. Several presentations discussed applying Biopharmaceutics Classification System (BCS) and in vitro–in vivo correlations in development and in post-development and discussed both resource savings and best scientific practices. The workshop also focused on evolving bioequivalence approaches, with emphasis on highly variable products (HVDP), as well as specialized modified-release products. In USA, two bioequivalence approaches for HVDP are the reference-scaled average bioequivalence approach and the two-stage group-sequential design. An adaptive sequential design approach is also acceptable in Canada. In European Union, two approaches for HVDP are a two-stage design and an approach to widen Cmax acceptance limits. For some specialized modified-release products, FDA now requests partial area under the curve. Rationale and limitations of such metrics were discussed (e.g., zolpidem and methylphenidate). A common theme was the benefit of the scientific and regulatory community developing, validating, and harmonizing newer bioequivalence methodologies (e.g., BCS-based waivers and HVDP trial designs).
Authors and Affiliations
James E. Polli, Jack A. Cook, Barbara M. Davit, Paul A. Dickinson, Domenick Argenti, Nancy Barbour, Alfredo García-Arieta, Jean-Marie Geoffroy, Kerry Hartauer, Shoufeng Li, Amitava Mitra, Francis X. Muller, Vivek Purohit, Manuel Sanchez-Felix, John W. Skoug, Kin Tang
Keywords
Related Articles
- EP ID EP681252
- DOI 10.1208/s12248-012-9376-z
- Views 67
- Downloads 0
Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?
Predictive Models of Diffusive Nanoparticle Transport in 3-Dimensional Tumor Cell Spheroids
The rapidly evolving nanotechnology field highlights the need of better understanding the relationship between nanoparticle (NP) properties and NP transport in solid tumors. The present study tested the hypothesis that t...
Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells
Protein synthesis is a powerful therapeutic target in leukemias and other cancers, but few pharmacologically viable agents are available that affect this process directly. The plant-derived agent silvestrol specifically...
Polymeric Nanocarriers for Transport Modulation across the Pulmonary Epithelium: Dendrimers, Polymeric Nanoparticles, and their Nanoblends
The online version of this article (doi:10.1208/s12248-014-9588-5) contains supplementary material, which is available to authorized users.
Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy
Anemia is frequently observed in patients undergoing chemotherapy. Administration of darbepoetin alfa, a recombinant erythropoiesis-stimulating agent that has longer residence time than endogenous erythropoietin, to pati...